Cholesterol Absorption Inhibitors Drug-Drug Interaction Table

What Is the Cholesterol Absorption Inhibitor Drug Class?

Cholesterol absorption inhibitors are a pharmacological class defined by selective inhibition of the Niemann-Pick C1-Like 1 (NPC1L1) protein, the principal transporter responsible for absorbing both dietary and biliary cholesterol across the jejunal brush-border membrane. Ezetimibe is the only FDA-approved member of this class. Approved in October 2002, it is indicated as an adjunct to diet for primary hyperlipidemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia (HoFH) [1].

Mechanism of Action at the Molecular Level

NPC1L1 is a 1,332-amino-acid transmembrane protein that shuttles unesterified cholesterol from the intestinal lumen into enterocytes via clathrin-mediated endocytosis. Ezetimibe glucuronide, the active metabolite, binds NPC1L1 directly and arrests its endocytic cycling, reducing cholesterol uptake by approximately 54 percent in human jejunal preparations [2]. The liver responds with compensatory upregulation of LDL receptors, which accelerates plasma LDL-C clearance. This receptor-driven clearance mechanism is additive with statins, which also upregulate LDL receptors through a separate pathway (HMG-CoA reductase inhibition).

Pharmacokinetics Relevant to DDIs

After oral dosing, ezetimibe undergoes rapid glucuronidation in the intestinal wall, producing ezetimibe-glucuronide, which recirculates enterohepatically. Mean half-life is 22 hours for both parent and active metabolite, allowing once-daily dosing. The drug is not a CYP450 substrate, CYP inhibitor, or CYP inducer at therapeutic concentrations. Key pharmacokinetic DDI vulnerabilities are: UGT enzyme competition, P-glycoprotein (P-gp) efflux modulation, and physical adsorption to bile acid sequestrants [3].

Ezetimibe Drug-Drug Interaction Table

The table below rates each interaction by severity (Major, Moderate, Minor) and provides the recommended clinical action. "Major" means the combination should generally be avoided or requires mandatory monitoring. "Moderate" means use with caution and consider dose adjustment. "Minor" means the interaction is statistically detectable but rarely requires action.

| Interacting Drug / Class | Severity | Mechanism | Effect on Ezetimibe or Co-drug | Clinical Action | |---|---|---|---|---| | Cyclosporine | Major | P-gp inhibition + reduced renal clearance | Ezetimibe AUC increases up to 12-fold; cyclosporine AUC also rises ~15% | Monitor cyclosporine levels; use lowest effective ezetimibe dose; consider alternative lipid-lowering | | Bile acid sequestrants (cholestyramine, colesevelam, colestipol) | Moderate | Physical adsorption in GI lumen | Ezetimibe AUC reduced ~55% with cholestyramine co-administration | Give ezetimibe at least 2 hours before or 4 hours after sequestrant | | Gemfibrozil | Moderate | UGT inhibition + OATP competition | Ezetimibe total AUC increased ~1.7-fold | Combination permissible but monitor for myopathy if a statin is part of regimen; gemfibrozil-statin combinations independently carry myopathy risk | | Fenofibrate | Minor | Mild UGT competition | Modest ~48% rise in ezetimibe AUC; fenofibrate AUC unchanged | No dose adjustment needed; monitor LFTs as with any fibrate use | | Statins (atorvastatin, rosuvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, pitavastatin) | Minor (pharmacokinetic) | No significant PK interaction with most statins | No clinically relevant change in statin or ezetimibe AUC for most pairs | No dose adjustment required; simvastatin dose capped at 40 mg/day in combination per FDA label guidance [4] | | Warfarin | Minor | Theoretical: altered vitamin K absorption | Prothrombin time and INR showed no clinically significant change in controlled studies | No routine dose adjustment; check INR within 2 weeks of starting or stopping ezetimibe in patients on warfarin | | Antacids (aluminum/magnesium hydroxide) | Minor | Reduced rate of absorption | Cmax reduced ~30%; AUC unchanged | No clinical action required; effect on total exposure is negligible | | Cimetidine | Minor | P-gp modulation | Ezetimibe Cmax modestly elevated | No clinical action required | | Rifampin (rifampicin) | Moderate | P-gp induction + possible UGT induction | Ezetimibe AUC reduced ~50% | Avoid combination when possible; if rifampin is medically necessary, expect attenuated lipid response and consider alternative agents | | Digoxin | Minor | P-gp competition | No significant change in digoxin steady-state AUC | No dose adjustment; routine digoxin monitoring per standard practice | | Oral contraceptives (ethinyl estradiol/levonorgestrel) | Minor | Enterohepatic recycling competition | Minor increase in ethinyl estradiol AUC; not clinically meaningful | No dose adjustment; document interaction in chart | | Niacin (nicotinic acid, high-dose) | Minor | Additive LDL-C lowering; no PK interaction identified | No significant PK change | No dose adjustment required; combination is additive for LDL-C reduction | | Amiodarone | Minor | P-gp inhibition | Modest rise in ezetimibe exposure possible | No routine dose adjustment; monitor for ezetimibe-related hepatotoxicity signs in patients with baseline hepatic dysfunction | | Lomitapide | Minor | Additive lipid-lowering; no formal PK study | No known PK interaction; additive LDL-C reduction | Used in HoFH regimens; document rationale | | Evolocumab / Alirocumab (PCSK9 inhibitors) | None significant | Different mechanisms; no shared metabolic pathway | No PK interaction | Safe combination; used in high-risk patients for additive LDL-C reduction |

Sources for the DDI table: FDA prescribing information for ezetimibe [1], the ACC/AHA 2018 Blood Cholesterol Guideline [5], and the primary pharmacokinetic interaction studies accessible via PubMed [3].

Cyclosporine Interaction: The Highest-Risk DDI

The cyclosporine-ezetimibe interaction deserves its own section because the magnitude is clinically dangerous. Cyclosporine inhibits P-glycoprotein and several organic anion-transporting polypeptides (OATP1B1, OATP1B3), reducing hepatic uptake and biliary excretion of ezetimibe-glucuronide [6].

Magnitude of Exposure Increase

In a formal PK study in renal transplant patients, co-administration of cyclosporine 75 to 150 mg twice daily raised the AUC of total ezetimibe (parent plus glucuronide) by a median of 3.4-fold, with individual patients showing increases up to 12-fold [6]. The cyclosporine AUC itself rose approximately 15 percent, which is relevant because cyclosporine has a narrow therapeutic index.

Recommended Management

The FDA label recommends avoiding the combination when possible [1]. If ezetimibe is the only practical option for lipid lowering in a transplant patient on cyclosporine, use the lowest dose (10 mg/day, the only approved dose), monitor cyclosporine trough levels more frequently in the first four to eight weeks, and obtain baseline and follow-up liver function tests. Switching the immunosuppressant to tacrolimus eliminates the OATP inhibition concern, though the prescribing team must weigh immunological risk.

Bile Acid Sequestrant Interaction: A Timing Problem, Not a Contraindication

Cholestyramine at 4 g twice daily reduces ezetimibe AUC by approximately 55 percent when the two drugs are given simultaneously [3]. The mechanism is simple adsorption: ezetimibe and its glucuronide bind to the resin matrix in the intestinal lumen before absorption can occur.

Spacing Protocol

Administer ezetimibe at least 2 hours before or 4 hours after any bile acid sequestrant. This timing window preserves full ezetimibe bioavailability. Colesevelam has a slightly lower adsorptive capacity than cholestyramine for ezetimibe, but the same spacing rule applies to avoid any meaningful reduction.

Why the Combination Is Still Prescribed

Despite the timing requirement, ezetimibe plus a bile acid sequestrant offers complementary mechanisms: sequestrants block reabsorption of bile acids (driving hepatic LDL receptor upregulation), while ezetimibe blocks direct sterol absorption. The 2018 ACC/AHA guideline recognizes both as non-statin options for LDL-C reduction in patients who cannot tolerate statins or need additional lowering beyond statin therapy [5].

Gemfibrozil and Other Fibrates: Distinguishing the Risk

Gemfibrozil is a potent UGT inhibitor and OATP competitor. It raises total ezetimibe AUC approximately 1.7-fold in healthy volunteers [3]. The clinical concern is not ezetimibe toxicity per se; ezetimibe has a wide therapeutic index. The concern is that gemfibrozil independently and powerfully increases statin exposure when a statin is part of the regimen, creating additive myopathy risk. Gemfibrozil is contraindicated with simvastatin and raises lovastatin and other statin levels substantially [4].

Fenofibrate is a much weaker UGT competitor. It raises ezetimibe AUC by roughly 48 percent without a corresponding increase in myopathy signal in clinical use. The 2018 ACC/AHA guideline considers fenofibrate an acceptable combination partner for moderate-intensity statin therapy when triglyceride reduction is needed alongside LDL-C management [5].

Ezetimibe in Combination with Statins: The IMPROVE-IT Trial

The most clinically important combination is ezetimibe plus a statin, and IMPROVE-IT (N=18,144) provides the definitive outcomes data. Patients with recent acute coronary syndrome were randomized to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. Over a median of 6 years, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm. The primary composite cardiovascular endpoint (CV death, major coronary event, or non-fatal stroke) occurred in 32.7 percent of combination patients versus 34.7 percent of placebo patients, a statistically significant absolute risk reduction of 2.0 percent (hazard ratio 0.936, 95% CI 0.887 to 0.988, P<0.001) [7].

This confirmed that LDL-C lowering below the then-standard statin target produces additional cardiovascular benefit, regardless of the pharmacological mechanism used to achieve it. The ACC/AHA 2018 guideline authors cited IMPROVE-IT directly to support adding ezetimibe in very-high-risk patients who remain above the LDL-C threshold on maximally tolerated statin therapy [5].

Simvastatin Dose Cap in the Ezetimibe Combination

The FDA label for Vytorin (ezetimibe/simvastatin) caps the simvastatin component at 40 mg/day. This is not a PK interaction between ezetimibe and simvastatin; it reflects the independent FDA 2011 simvastatin 80 mg dose restriction due to myopathy risk [4]. Prescribers who need LDL-C reduction beyond what simvastatin 40 mg plus ezetimibe achieves should switch to a higher-potency statin (rosuvastatin or atorvastatin) rather than increasing simvastatin.

Rifampin and P-glycoprotein Inducers: The Underappreciated Interaction

Rifampin induces both P-glycoprotein and UGT enzymes. A single 600 mg dose of rifampin given simultaneously with ezetimibe increased ezetimibe Cmax transiently, but repeat rifampin dosing (chronic induction state) reduced ezetimibe AUC by approximately 50 percent [3]. This means patients on rifampin for tuberculosis or atypical mycobacterial infections may have substantially attenuated lipid-lowering responses to ezetimibe.

Pravastatin or rosuvastatin, which are minimally CYP3A4-dependent, are generally preferred over simvastatin or lovastatin in patients requiring rifampin, though all statin-rifampin combinations require careful LDL-C monitoring [5].

Special Populations and Dosing Adjustments

Renal Impairment

No dose adjustment is required in any degree of renal impairment. Ezetimibe and its glucuronide conjugate are excreted primarily in feces (78 percent), with only 11 percent appearing in urine [1]. Hemodialysis does not meaningfully affect ezetimibe clearance.

Hepatic Impairment

The FDA label contraindicates ezetimibe in moderate to severe hepatic impairment (Child-Pugh score B or C) because enterohepatic recycling of the glucuronide is impaired, leading to unpredictable and elevated ezetimibe exposure [1]. Mild hepatic impairment (Child-Pugh A) does not require dose adjustment; ezetimibe AUC rises modestly but remains within the safe range observed in clinical trials.

Pediatric Use

Ezetimibe 10 mg daily is approved for children aged 10 years and older with heterozygous familial hypercholesterolemia. PK parameters in adolescents are comparable to adults. No pediatric DDI data differ meaningfully from adult data [1].

Pregnancy and Lactation

Ezetimibe is contraindicated in pregnancy (Category X when combined with a statin). Animal studies showed skeletal abnormalities at supratherapeutic doses, and cholesterol is required for fetal development. Ezetimibe passes into human milk at low levels; the manufacturer recommends against use during breastfeeding [1].

Monitoring Parameters for Patients on Ezetimibe

The following framework organizes monitoring by time point and clinical context:

Baseline (before starting):

• Fasting lipid panel (LDL-C, HDL-C, non-HDL-C, triglycerides)
• Liver function tests (ALT, AST) if hepatic impairment is suspected
• Current medication list reviewed for cyclosporine, gemfibrozil, bile acid sequestrants, and rifampin

4 to 12 weeks after starting or changing dose:

• Repeat fasting lipid panel to confirm LDL-C response
• If on cyclosporine: cyclosporine trough level and serum creatinine

Ongoing (every 3 to 12 months depending on risk tier):

• Fasting lipid panel per ACC/AHA ASCVD risk-based interval
• No routine LFT monitoring required unless symptoms develop or patient has baseline hepatic vulnerability

Trigger-based monitoring:

• Any new muscle symptoms: CK level, though ezetimibe monotherapy myopathy is rare
• New jaundice, right upper quadrant pain, or fatigue: LFTs and hepatitis serologies

The 2022 ACC Expert Consensus on Non-Statin Therapies states: "Ezetimibe does not require routine laboratory safety monitoring beyond lipid response assessment in the absence of specific comorbidities or interacting medications." [8]

Ezetimibe Compared to Other Non-Statin LDL-C Lowering Agents

Understanding where ezetimibe fits in the non-statin hierarchy matters for prescribing decisions when statins are insufficient or not tolerated.

| Agent | LDL-C Reduction | Route | Cost | DDI Burden | Outcomes Data | |---|---|---|---|---|---| | Ezetimibe 10 mg/day | 18 to 20% monotherapy; add-on 23 to 24% | Oral daily | Low (generic available) | Moderate (cyclosporine, sequestrants, gemfibrozil) | IMPROVE-IT: CV event reduction confirmed [7] | | Evolocumab (PCSK9 inhibitor) | 60 to 70% | Subcutaneous every 2 weeks or monthly | High | Very low | FOURIER: HR 0.85 for CV events [9] | | Alirocumab (PCSK9 inhibitor) | 48 to 60% | Subcutaneous every 2 weeks or monthly | High | Very low | ODYSSEY OUTCOMES: HR 0.85 for CV events [10] | | Inclisiran (siRNA) | 50 to 55% | Subcutaneous every 6 months | High | Very low | ORION-10: 52.3% LDL-C reduction [11] | | Bempedoic acid | 18 to 22% | Oral daily | Moderate | CYP2C9 interactions; simvastatin/pravastatin AUC rise | CLEAR Outcomes: HR 0.87 for CV events [12] | | Colesevelam | 15 to 18% | Oral (packets or tablets) | Moderate | High (adsorbs many drugs) | No CV outcomes RCT |

The ACC/AHA 2022 decision pathway recommends adding ezetimibe as the first non-statin agent in patients with atherosclerotic cardiovascular disease (ASCVD) who remain above LDL-C 70 mg/dL on maximally tolerated statin therapy, before escalating to a PCSK9 inhibitor [8].

Clinical Scenarios Where the DDI Table Changes Management

Scenario 1: Post-Transplant Hyperlipidemia on Cyclosporine

A 52-year-old heart transplant recipient on cyclosporine 200 mg twice daily has LDL-C of 118 mg/dL despite pravastatin 40 mg. Adding ezetimibe 10 mg carries a cyclosporine AUC increase of roughly 15 percent and a potential 3 to 12-fold rise in ezetimibe exposure. The safest approach is to check a cyclosporine trough before starting ezetimibe, then recheck at two and six weeks. An alternative: confirm whether the patient can safely transition to tacrolimus, which does not inhibit OATP1B1/1B3 to the same degree.

Scenario 2: Bile Acid Sequestrant Plus Ezetimibe for Statin-Intolerant Patient

A 67-year-old woman with statin myalgia confirmed by re-challenge needs LDL-C lowering. She is currently on colesevelam 3.75 g/day (six tablets). Adding ezetimibe is appropriate. She should take ezetimibe 10 mg with breakfast and colesevelam tablets with dinner to maintain the minimum 2-hour separation, preserving full ezetimibe bioavailability.

Scenario 3: Tuberculosis Treatment with Rifampin in a Patient on Ezetimibe

A patient stabilized on ezetimibe plus atorvastatin 40 mg starts rifampin-based TB therapy. Expect ezetimibe efficacy to fall significantly (roughly 50 percent AUC reduction). Increase LDL-C monitoring frequency to every four weeks for the first two months of rifampin therapy. Consider adding or increasing atorvastatin dose rather than increasing ezetimibe, since atorvastatin's CYP3A4-mediated metabolism is also induced by rifampin; if LDL-C rises substantially, rosuvastatin (less CYP3A4-dependent) at 20 to 40 mg may be a better backbone statin during TB therapy [5].